1 With the advent of rituximab, overall survival and progression-free survival rates have improved; however, about half of FL patients experience relapse within 5 years, representing a considerable setback. 2 Definitive explanation for relapse is not fully disclosed, although several unresolved theories have been offered, pertaining to genomic or clonal evolution, microenvironment and other elements. [3] [4] [5] [6] Concretely, these recent studies reported several specific gene mutations including TNFRSF14, CREBBP, EP300, KLHL6 and so on that were supposed to be critical for immune evasion, biological transformation and progression of FL, [3] [4] [5] [6] which provided the basis of lymphoma-initiating cells from the point of genomic DNA mutations.
For advanced tumor therapeutics in carcinomas, glial malignancies and leukemias, so-called cancer initiating cells or cancer stem cells, have presently been recognized as key factors in relapse and therapeutic resistance. [7] [8] [9] Cancer stem cells (CSC) in solid tumors have been vigorously studied; however, CSC, analogously lymphoma stem cells in lymphoma, were mainly introduced for limited subtypes of lymphoma such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Hodgkin lymphoma, and more information should be collected about other types of lymphomas, especially intractable lymphomas including FL. 10, 11 To identify cancer stem cells, previous reports used several markers (eg, OCT4, SOX2, KLF4, Nanog, SSEA-4, and ALDH1), among which the former three were genes to induce mouse or human somatic cells to become pluripotent stem cells. 12, 13 These markers needed to be used in combination, but, recently, several groups discovered a new marker TRA-1-60 which imparted stronger stem cell properties than other markers. 14,15 TRA-1-60 is a neuraminidase-resistant carbohydrate epitope expressed on podocalyxin-like 1, belonging to the CD34-related family of sialomucin, and it is expressed on the surface of human embryonic stem cells (ESC) and induced pluripotent stem cells (iPS cells), which becomes downregulated as cell-differentiated. 16 In the present study, we aimed to find a clue for the intractability of FLs which causes relapse and drug resistance, leading to fatal outcomes despite the current advanced therapeutics using antibody drug. Therefore, we first histologically examined TRA-1-60 expression on FL tissues and germinal centers as its origin in order to examine correlation with expression of cellular markers including conventional stem cell markers such as Oct3/4 and ALDH1, which provide biological insight on cellular properties, as TRA-1-60 is one of the critical cellular markers of stem cells. We observed a rare population of follicular lymphoma cells specifically expressing TRA-1-60
as well as germinal center B cells. Remarkably, we found that the number of TRA-1-60-positive cells increased in the recurrent samples that resisted therapy, and they showed prominent drug resistance and tumor-forming capacity, properties not observed in the TRA-1-60-negative FL population by in vitro assays using two different human FL cell lines. Our results indicate that TRA-1-60, which might provide follicular lymphoma cells with resistant properties against lymphoma therapeutics, is expressed in a small population of FL cells, and this specific population could be highly significant to explain the recalcitrance of FL. (Tables 1 and 2 ). This study was conducted with the approval of the Institutional Review Board of Okayama University, Okayama, Japan. All study procedures were conducted in accordance with the guidelines of the Declaration of Helsinki.
| MATERIAL S AND ME THODS

| Patient samples
| Immunohistochemistry, immunofluorescence, and measurement of TRA-1-60-expressing lymphoma cells in patient samples
For conventional immunohistochemistry and fluorescent immunostaining of paraffin-embedded tumor tissues, primary and secondary antibodies were used as listed in Table 3 . Number of TRA-1-60-positive cells in reactive tissues and FL tissues was counted at a total of nine high-power fields (HPF) (×400 field) of randomly chosen perivascular areas in the same specimen.
| Laser capture microdissection, longdistance PCR for t(14;18) and DNA sequencing of PCR products
Laser capture microdissection was carried out for freshly frozen sections using the Leica LMD 7000 laser microdissection system (Leica Microsystems, Wetzlar, Germany) as previously described. 17 Briefly, 15 to 20 TRA-1-60-positive or TRA-1-60-negative cells were to be vigorously intractable against conventional therapeutic agents, which may explain its refractory recurrence.
K E Y W O R D S
drug resistance, follicular lymphoma, rituximab, TRA-1-60, tumor recurrence collected and total DNA was isolated by Qiagen tissue microkit (QIAGEN, Hilden, Germany). Long-distance PCR was carried out as described in a previous report. 18 When we did not obtain any amplification, re-amplification was done using 0.5 μL of first-round PCR product. Primer sets are shown in Table 4 . Primers for sequencing the PCR products to confirm bcl-2-IgH gene fusion are listed in Table 4 as reported previously. 18 Sequences of IgH and bcl-2 gene loci were searched by UCSC genome browser (https://genome.ucsc.edu/). Detailed methods of each of the above sections are described in "Document S1". was expressed on a comparable number of follicular dendritic cells (FDC) inside the germinal center ( Figure 1D and Figure S1A ). TRA-1-60 expression was mainly independent of ALDH1A1 expression inside the germinal center ( Figure 1E ). Moreover, the TRA-1-60-expressing germinal center B cells were negative for Ki-67, suggesting they were quiescent in the cell cycle ( Figure 1F ).
| Cell lines and drug treatment assay
| Distribution of TRA-1-60-positive cells in FL tissues
Insofar as the neoplastic counterpart to the normal lymphoid follicle, Patient information of these cases is provided in Table 1 . Scattered TRA-1-60-expressing CD20-positive B cells were mainly detected at the marginal area of neoplastic follicles of FL, close to small blood vessels indicated as "HEV" (Figure 2A upper and lower panels). TRA-1-60-positive cells were independent of CD21-positive FDC in FL tissues ( Figure S1B ). Moreover, they were negative for Ki-67 whereas some ALDH1A1-expressing cells were positive for Ki-67 ( Figure 2D ,E), suggesting that these TRA-positive cells were in cell cycle arrest. For confirmation of specificity of all histological staining using anti-TRA-1-60 antibody, tissue staining with mouse IgM as a control was carried out ( Figure S1C ).
| TRA-1-60-expressing cells are neoplastic in FL tissues
Based on the immunofluorescence results, we further examined whether TRA-1-60-positive cells in FL tissues were neoplastic.
Accordingly, single cell microdissection was used to isolate TRA-1-60-positive cells from patient specimens ( Figure 3A , left panel, indicated by dotted circles). After extraction of genomic DNA from five to 10 isolated cells on the same specimen, long-distance PCR was first carried out, then sequentially semi-nested PCR was done using the first amplicon to demonstrate the specific gene fusion, t(14;18/IGH-BCL2) ( Table 4) Tables S5 and S6 ).
In detail, expression of ABC transporters including ABCA13, ABCB11, ABCB5, SLCO1B3 on TRA-1-60-positive cells was increased more than three-fold (Table S5) (Table   S6 ). Moreover, some of the tumor-related transcription factors and receptors such as Fos, TNFRSF11a (over three-fold), followed by MET,
CDKN2D, EGFR, ERBB4, ESR2, MVP, SULTE1
and NFkBIE etc. were induced by their expression in the TRA-1-60-positive population compared with those in the negative population (Table S6) 
| D ISCUSS I ON
For most B-cell lymphomas, it is widely accepted that rituximab has contributed to disease-free survival. 25 However, a serious clinical concern, especially for intractable lymphomas, is frequent tumor relapse under rituximab treatment and one of these is represented by follicular lymphomas. Recently, the concept of the "cancer initiating cell" has gained traction for explaining therapeutic failure and relapse for several types of malignancies, because of their therapeutically resistant feature against antitumor agents and irradiation. 21 In the meantime, studies in the field of regenerative medicine have provided information about several critical cellular markers such as Oct3/4 and ALDH1 for identifying the stem cell, and TRA-1-60 has been reported as the most reliable indicator among these. 14 In the present study, our aim was to find a clue for such recalcitrance of follicular lymphomas, which may clinically lead to recurrence and fatal Recently, besides the current standard chemotherapy of R-CHOP, treatment by bendamustine combined with rituximab has emerged as a more effective therapy for relapsed or refractory FL. This advanced therapy is reported to improve progression-free survival, 26 and is expected to be the first-line treatment approach going forward.
However, TRA-1-60-positive populations showed pronounced resistance to bendamustine as well as to rituximab, which may be partly explained by simultaneous upregulation of diverse isotypes of ABC transporter and CYP genes as was demonstrated by expression profiling, held to impart resistance to antitumor agents. Moreover, several genes such as Fos, MET, NFkBIE, and TNFRSF11a (also known as RANK)
were found to be upregulated in TRA-1-60-expressing FL cells, which have been reported to play diverse roles in tumorigenesis, intractability against therapeutics, and induction of stem-like phenotype to tumors. 27, 28 Especially, upregulation of c-Fos, an immediate early transcription factor gene, was the most remarkable; however, its concrete function in TRA-1-60-expressing FL cells remains unclear in this study.
We conclude that, although further investigation for molecular insights will be necessary, it is now clear that TRA-1-60 should be a prominent focus among cellular markers in follicular lymphoma research, by which we ultimately hope to explain clinical intractability against current rituximab-combination and other therapies, and to better understand the unique population among a range of lymphoma cell types. from the Japan Society for the Promotion of Science (JSPS).
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